// App-Quantinova.ai

: Incidence of inhibitors in previously untreated patients with severe haemophilia a treated with rFVIIIFc: The PUPs A‐LONG study

Researchers

Presenter

  • C. Knigs

Principal Investigators

  • R. Liesner

  • M. C. Ozelo

  • A. D. Shapiro

  • S. A. Brown

  • A. Innes

  • B. Winding

  • C. Reuter

  • D. Rudin

  • M. Carcao

Medical Centers

  • University Hospital Frankfurt, Frankfurt, Germany

  • Great Ormond Street Hospital, London, United Kingdom

  • Hemocentro UNICAMP, University of Campinas, Campinas, São Paulo, Brazil

  • Indiana Haemophilia andThrombosis Center, Indianapolis, IN, United States

  • Royal Brisbane & Womens Hospital, Queensland Haemophilia Centre, Brisbane, Australia

  • Bioverativ, a Sanofi Company, Waltham, MA, United States

  • Sobi, Stockholm, Sweden

  • Hospital for Sick Children, Toronto, ON, Canada

Locations

  • Germany

  • United Kingdom

  • Brazil

  • United States

  • Australia

  • Sweden

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • FVIIIFc

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Bioverativ

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved